ClinicalTrials.gg
Active, not recruitingNCT04961710Updated Sep 19, 2024

Extension Study of Hetrombopag in Severe Aplastic Anemia

A Phase 3 interventional study of Hetrombopag Olamine and Placebo in Treatment-naive Severe Aplastic Anemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 9 months after the study started (first participant enrolled Sep 2019, registered Jul 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Non-randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Anemia, Aplastic with a site in China — 40 open to participants now, 44 under way, 1 of them phase 3. Anemia, Aplastic · China.

Enrollment
8th of 74
157 · median 52
Started
2019
with 2 others
Phase 3
2 of 89
none open now
Primary completion
2024-11
later than 4 of 43 live
Registered
30th of 89
by date
Lead sponsor
7 of 89
Jiangsu HengRui Medicine Co., Ltd.

Among the 89 studies in Anemia, Aplastic with a site in China, this one is the 8th largest by enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 3, reaches primary completion later than 4 of the 43 other live ones, and was the 30th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

40 of the 89 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with treatment-naive severe aplastic anemia. All subjects who have completed or withdrawn from the HR-TPO-SAA-III study will voluntarily participate in this extension study.

Subjects will receive the same study drug (hetrombopag or placebo) as in study HR-TPO-SAA-III, with the same doses and administration schedule or with modifications based on the actual conditions.

The primary objective of this extension study is to give the subjects participating in the HR-TPO-SAA-III study the continued access to the study drug (hetrombopag or placebo) after the completion of the HR-TPO-SAA-III study.

03

Conditions studied

  • Treatment-naive Severe Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have completed or withdrawn from the HR-TPO-SAA-III study
  2. Subjects who have signed the form
  3. Female and male subjects of childbearing age who agree to take adequate measures during the extension study period and within 28 days after the last dose
  4. Subjects who have completed the end-of-treatment evaluation in the original study

Exclusion criteria

Exclusion Criteria:

  1. Any unstable situation or situation that will compromise the safety of the subject
  2. Evidence of clonal cytogenetic abnormalities at the end-of-treatment examination of the HR-TPO-SAA-III study
  3. Subjects with uncontrollable hemorrhage and/or infection after standard treatment
  4. Subjects who have experienced deep vein thrombosis, myocardial infarction, stroke, or peripheral arterial embolism within 1 year
  5. Any situation that may compromise the subject and the safety or compliance thereof during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Hetrombopag Olamine

    Drug: Hetrombopag Olamine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The ratio of subjects with clonal evolution at 6 months and 18 months

    Time frame: 6 months and 18 months

  2. All SIEs, regardless of whether they are related to the investigational product

    Time frame: 3 years

  3. All SAEs, regardless of whether they are related to the investigational product

    Time frame: 3 years

  4. All AEs resulting in discontinuation and withdrawal from study

    Time frame: 3 years

Secondary outcomes

  1. Red blood cell count

    Time frame: by 1day visit

  2. Hemoglobin

    Time frame: by 1day visit

  3. Platelet count

    Time frame: by 1day visit

  4. White blood cell count

    Time frame: by 1day visit

  5. Neutrophil count

    Time frame: by 1day visit

  6. Reticulocyte count

    Time frame: by 1day visit

  7. The 6-month and 18-month survival rates of subjects

    Time frame: 6 months and 18 months

  8. The recurrence rates at 6 months and 18 months

    Time frame: 6 months and 18 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2019 (actual). Primary completion is estimated for Nov 2024, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Jul 14, 2021
StartActual
Sep 19, 2019
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04961710
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
Sep 19, 2019
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 19, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion